Breaking News: Foghorn Therapeutics Doses First Patient in Revolutionary AML Study!
Today, a groundbreaking development in the field of biotechnology has taken place. Foghorn® Therapeutics Inc., a clinical-stage biotechnology company, has announced the dosing of the first patient in the Phase 1 study of FHD-286 in combination with decitabine or cytarabine in relapsed and/or refractory acute myeloid leukemia (AML). This news marks a significant milestone in…